ARMA BIO, INC.

Biotech · Private

Dual inhibitors of androgen receptor full-length and androgen receptor splice variants for castration-resistant prostate cancer

Grants
$2.5M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Development of small molecule therapeutics targeting AR-V7 for prostate cancer$406,489
Federal grantDepartment of Health and Human Services · Phase II · Development of small molecule therapeutics targeting AR-V7 for prostate cancer$55,000
Federal grantDepartment of Health and Human Services · Phase II · Development of small molecule therapeutics targeting AR-V7 for prostate cancer$1,150,471
Federal grantDepartment of Health and Human Services · Phase II · Development of small molecule therapeutics targeting AR-V7 for prostate cancer$888,779
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2692OOMNI, INC.——
2693STEMMED, LTD——
2694Sangamo Therapeutics——
2695ARMA BIO, INC.——
2696IGE THERAPEUTICS, INC.——
2697SUDHIN BIOPHARMA COMPANY——
2698MC1R VENTURES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.